US FDA approves AstraZeneca's self-administered nasal spray flu vaccine
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...
FDA approves first self-administered flu vaccine spray
The Food and Drug Administration announced Friday it had broadened the approval of the FluMist nasal spray to become the ...
US FDA approves AstraZeneca's flu vaccine for self-administration
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for ...
Sanofi, AstraZeneca win US approval for RSV therapy manufacturing line
Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...
FDA approves first self-administered flu vaccine
The vaccine FluMist, manufactured by MedImmune, which was acquired by AstraZeneca in 2007, was first approved by the FDA in 2003 for individuals between five and 49 years of age. Its approval has ...
WAPT1d
FDA approves first flu vaccine that can be self-administered at home
FluMist is a nasal spray manufactured by AstraZeneca that has been used to protect against influenza in the United States ...
devdiscourse5h
Regulatory Milestones and Health Advances: Key Developments in the Pharmaceutical Sector
Recent health news highlights key regulatory approvals and legal actions. The EU backs Novo Nordisk's Wegovy for an ...
AstraZeneca falls Friday, still outperforms market
AstraZeneca PLC AZN shares inched down 0.99% to £117.80 Friday, on what proved to be an all-around rough trading session for ...
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare vasculitis trial
The Phase III trial compared the efficacy of Fasenra with the standard treatment of GSK’s Nucala in patients with ...
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
The most recent trading session ended with Astrazeneca (AZN) standing at $78.38, reflecting a -0.66% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's ...
STAT6d
AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
If the trial design doesn't cause regulatory issues, the results could reshape how muscle-invasive bladder tumors are treated ...
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial ...